Kiora Pharmaceuticals (KPRX) to Post Earnings on Friday

Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) is anticipated to issue its Q2 2026 results before the market opens on Friday, August 7th. Analysts expect Kiora Pharmaceuticals to announce earnings of ($0.47) per share for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.58) earnings per share for the quarter, hitting the consensus estimate of ($0.58).

Get Kiora Pharmaceuticals alerts:

Kiora Pharmaceuticals Stock Up 2.8%

Shares of KPRX opened at $2.54 on Thursday. The firm has a market capitalization of $11.25 million, a PE ratio of -0.94 and a beta of -0.38. The firm has a 50-day moving average price of $2.58 and a 200 day moving average price of $2.36. Kiora Pharmaceuticals has a 52-week low of $1.76 and a 52-week high of $3.01.

Institutional Trading of Kiora Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of KPRX. Two Sigma Investments LP acquired a new stake in shares of Kiora Pharmaceuticals in the third quarter valued at $33,000. Renaissance Technologies LLC grew its holdings in Kiora Pharmaceuticals by 71.0% during the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock worth $42,000 after acquiring an additional 8,800 shares during the period. Citadel Advisors LLC acquired a new position in Kiora Pharmaceuticals during the third quarter worth about $125,000. Alyeska Investment Group L.P. bought a new stake in Kiora Pharmaceuticals in the fourth quarter worth about $152,000. Finally, DRW Securities LLC raised its position in Kiora Pharmaceuticals by 199.2% in the fourth quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock worth $217,000 after acquiring an additional 73,417 shares in the last quarter. Institutional investors own 76.97% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Kiora Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $10.00.

Check Out Our Latest Stock Analysis on KPRX

Kiora Pharmaceuticals Company Profile

(Get Free Report)

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.

Read More

• Five stocks we like better than Kiora Pharmaceuticals
• SpaceX: Love the Company, But the Stock Is a Harder Call
• Ulta’s Growth Is Real, But So Are the Risks
• BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
• Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth

Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.